Targeting the Mutation, Not the Disease is Bringing Treatment to the Ultra-Rare Community
Source: pixabay.com

Targeting the Mutation, Not the Disease is Bringing Treatment to the Ultra-Rare Community

The U.S. FDA just announced that it has accepted Genentech’s supplemental New Drug Application (sNDA) and has granted Priority Review for Zelboraf (vemurafenib) in patients with Erdheim-Chester disease from the…

Continue Reading Targeting the Mutation, Not the Disease is Bringing Treatment to the Ultra-Rare Community